May 15, 2025

The Centers for Medicare and Medicaid Services (CMS) announced the suspension of eight Merit-based Incentive Payment System (MIPS) Improvement Activities (IAs) for the 2025 performance year. They are:

  • IA_AHE_5: MIPS Eligible Clinician Leadership in Clinical Trials or CBPR.
  • IA_AHE_8: Create and Implement an Anti-Racism Plan.
  • IA_AHE_9: Implement Food Insecurity and Nutrition Risk Identification and Treatment Protocols.
  • IA_AHE_11: Create and Implement a Plan to Improve Care for Lesbian, Gay, Bisexual, Transgender, and Queer Patients.
  • IA_AHE_12: Practice Improvements that Engage Community Resources to Address Drivers of Health.
  • IA_PM_6: Use of Toolsets or Other Resources to Close Health and Health Care Inequities Across Communities.
  • IA_ERP_3: COVID-19 Clinical Data Reporting with or without Clinical Trial.
  • IA_PM_26: Vaccine Achievement for Practice Staff: COVID-19, Influenza, and Hepatitis B.

Although CMS advises clinicians to select alternative improvement activities when reporting to MIPS in 2025, practices that already completed or were in the process of completing these activities prior to May 6, can still receive credit for the activity.

CMS said it will post updated improvement activity specifications to the QPP Resource Library in the coming weeks.

If you have questions about 2025 MIPS participation or the suspended IAs, contact Zach Smith, American College of Radiology® Senior Quality Programs Specialist.

Related ACR News

  • CMS Releases 2026 Medicare Physician Fee Schedule Final Rule

    CMS released the 2026 MPFS final rule Oct. 31. ACR prepared an initial summary about impact on imaging.

    Read more
  • Massachusetts Legislature Updates Prior Authorization Bill

    Massachusetts HB 4616 aims to streamline prior authorization, boost transparency, and study its impact on care access and costs.

    Read more
  • ACR Responds to RFI on AI Regulatory Reform

    ACR urged the White House to enhance AI oversight and payment policies to support safe, effective, and reimbursable clinical AI use.

    Read more